Perrigo Company (NYSE:PRGO; TASE:PRGO) board of directors has rejected Mylan’s improved offer.
Mylan N.V. had for the second time raised its offer to buy US-Irish-Israeli generic pharmaceuticals concern Perrigo company. Mylan is now offering Perrigo shareholders $75 plus 2.3 Mylan shares per Perrigo share for a total of about $35.6 billion.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
The new offer reflects a share price of about $232.23 per Perrigo share based on prices on April 8 when Mylan made its first offer. The previous offer, which was rejected by Mylan, was for $222 per Perrigo share, comprising $60 in cash and 2.2 Mylan shares.
Published by Globes [online], Israel business news – www.globes-online.com